A61K 40/425
Caspases
Official title: {Caspases}
A61K40/425 (Caspases) appears on 3 US grants and 8 published applications in this corpus.
Search patents in A61K- Granted patents
- 3
- Published applications
- 8
- Assignees
- 9
- Inventors
- 20
- Latest grant
- 24 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 2 |
| 2024 | 2 | 0 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of isolating T cells having antigenic specificity for a cancer-specific mutation24 Dec 2024US 12,171,818 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same4 Jun 2024US 11,999,968 B2Fullhope Biomedical Co., Ltd.
- Methods of isolating T cells having antigenic specificity for a cancer-specific mutation13 Apr 2021US 10,973,894 B2The United States of America, as represented by the Secretary, Department of Health and Human
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells21 Aug 2025US 2025/0262301 A1Shoreline Biosciences, Inc.
- Methods of isolating t cells having antigenic specificity for a cancer-specific mutation20 Feb 2025US 2025/0059508 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Modified t cells, pharmaceutical composition, manufacturing method thereof, and method of using the same27 Apr 2023US 2023/0131917 A1Fullhope Biomedical Co., Ltd.
- Method of delivering nucleic acid to immune cells using rbcev20 Apr 2023US 2023/0121065 A1Cornell University
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.